Literature DB >> 26606965

Is all cancer therapy immunotherapy?

Marcia Belvin1, Ira Mellman2.   

Abstract

Researchers must renew efforts to decipher how standard chemotherapies enhance the effects of targeted immunotherapeutic agents (Müller et al., this issue).
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26606965     DOI： 10.1126/scitranslmed.aad7661

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  9 in total

Review 1.  Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Authors:  Theodore S Johnson; Tracy Mcgaha; David H Munn
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 2.  IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment.

Authors:  David H Munn; Madhav D Sharma; Theodore S Johnson; Paulo Rodriguez
Journal:  Cancer Immunol Immunother       Date:  2017-05-09       Impact factor: 6.968

Review 3.  Chemotherapy remains an essential element of personalized care for persons with lung cancers.

Authors:  M D Hellmann; B T Li; J E Chaft; M G Kris
Journal:  Ann Oncol       Date:  2016-07-25       Impact factor: 32.976

Review 4.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2016-01-31       Impact factor: 16.687

5.  Spontaneous CD4+ and CD8+ T-cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients.

Authors:  Hayden Pearce; Paul Hutton; Shalini Chaudhri; Emilio Porfiri; Prashant Patel; Richard Viney; Paul Moss
Journal:  Eur J Immunol       Date:  2017-06-26       Impact factor: 5.532

6.  Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805.

Authors:  Munetoshi Ando; Keiko Nagata; Kaito Nihira; Yui Suzuki; Yutaka Kanda; Maiko Adachi; Tsuguo Kubota; Naoya Kameyama; Mariko Nakano; Hiroshi Ando; Kazuya Yamano; Toshihiko Ishii; Ryuichiro Nakai; Kazuyasu Nakamura
Journal:  Transl Oncol       Date:  2017-07-12       Impact factor: 4.243

Review 7.  Nanomaterials for Protein Delivery in Anticancer Applications.

Authors:  Anne Yau; Jinhyung Lee; Yupeng Chen
Journal:  Pharmaceutics       Date:  2021-01-25       Impact factor: 6.321

8.  EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.

Authors:  Suresh Bugide; Romi Gupta; Michael R Green; Narendra Wajapeyee
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-27       Impact factor: 11.205

9.  Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage IV melanoma patients.

Authors:  Klaus Eisendle; Georg Weinlich; Susanne Ebner; Markus Forstner; Daniela Reider; Claudia Zelle-Rieser; Christoph H Tripp; Peter Fritsch; Patrizia Stoitzner; Nikolaus Romani; Van Anh Nguyen
Journal:  J Dtsch Dermatol Ges       Date:  2020-11-16       Impact factor: 5.584
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.